BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26588914)

  • 1. The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution.
    Chen A; Yang J; Hu S; Wang QF
    Sci China Life Sci; 2015 Dec; 58(12):1302-5. PubMed ID: 26588914
    [No Abstract]   [Full Text] [Related]  

  • 2. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
    Gu LF; Zhang WG; Wang FX; Cao XM; Chen YX; He AL; Liu J; Ma XR
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):997-1003. PubMed ID: 21152934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia.
    Fang B; Liu Y; Zhou J; Li Y; Song Y
    Am J Hematol; 2012 Jan; 87(1):126-7. PubMed ID: 22072502
    [No Abstract]   [Full Text] [Related]  

  • 5. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
    Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
    PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.
    Chen L; Yin Q; Mi R; Wei X
    Leuk Lymphoma; 2013 Oct; 54(10):2291-3. PubMed ID: 23369043
    [No Abstract]   [Full Text] [Related]  

  • 7. Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Liu H; Zhang J; Ren S; Chen M; Liu L; Zhang H
    Leuk Lymphoma; 2017 Nov; 58(11):2758-2761. PubMed ID: 28406352
    [No Abstract]   [Full Text] [Related]  

  • 8. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
    Wang Y; Li W; Chen S; Qiu H; Sun A; Wu D
    Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia.
    Chen C; Xu W; Yang J
    Leuk Lymphoma; 2015 Jan; 56(1):141-6. PubMed ID: 24724783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
    Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A homoharringtonine-based regimen for childhood acute myelogenous leukemia.
    Tang J; Xue H; Pan C; Chen J; Gu L; Zhao H
    Med Pediatr Oncol; 2003 Jul; 41(1):70-2. PubMed ID: 12764750
    [No Abstract]   [Full Text] [Related]  

  • 16. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
    Saito K
    Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.
    Filanovsky K; Shvidel L; Shtalrid M
    J Clin Oncol; 2010 Mar; 28(7):e115-6; author reply e117-8. PubMed ID: 20100951
    [No Abstract]   [Full Text] [Related]  

  • 18. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.
    Suzushima H; Wada N; Yamasaki H; Eto K; Shimomura T; Kugimiya MH; Horikawa K; Nishimura S; Tsuda H; Mitsuya H; Asou N
    Leuk Res; 2010 May; 34(5):610-4. PubMed ID: 19744710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy of relapsed AML and ALL].
    Nishikawa K
    Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.